The evaluation of diverse AMPs, such as C14R, as possible alternatives to effectively manage and address the global issue of antifungal resistance is a key step forward to advance in the ability to treat patients with invasive mycoses such as candidiasis. This evidence concerns the gene ADSL and fungal infectious disease.